



Condensed Consolidated Interim Financial Statements
(Expressed in Canadian Dollars)

WAVERLEY PHARMA INC.

Three and nine months ended September 30, 2025
(unaudited)

In accordance with National Instruments 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2025.



Condensed Consolidated Interim Statements of Financial Position
(expressed in Canadian dollars)
(unaudited)

	Note	September 30, 2025	December 31, 2024
Assets			
Current assets:			
Cash		\$ 67,632	\$ 235,929
Accounts receivable	4	55,779	208,681
Inventory	5	260,149	261,485
Prepaid expenses		8,155	23,625
Total current assets		391,715	729,720
Non-current assets			
Property and equipment		233,404	263,396
Intangible assets	7	344,208	397,944
Goodwill	3	216,289	223,560
Non-current assets held-for-sale	8	-	264,520
Other asset	9(d)	88,385	166,669
Total non-current assets		882,286	1,316,089
Total assets		\$ 1,274,001	\$ 2,045,809
Liabilities and Equity			
Current liabilities:			
Accounts payable and accrued liabilities		\$ 411,337	\$ 1,010,960
Bank indebtedness	6	2,990,429	2,810,383
Income taxes payable		806	-
Current portion of lease obligation		43,904	37,116
Total current liabilities		3,446,476	3,858,459
Non-current liabilities			
Lease obligation		189,052	218,912
Total non-current liabilities		189,052	218,912
Total liabilities		3,635,528	4,077,371
(Deficit) Equity:			
Share capital	9(b)	7,000,100	7,000,100
Warrants	9(d)	521,894	521,894
Contributed surplus		809,420	809,420
Accumulated other comprehensive loss		(48,814)	(20,755)
Deficit		(10,644,127)	(10,342,221)
Total (deficit) equity		(2,361,527)	(2,031,562)
Total liabilities and equity		\$ 1,274,001	\$ 2,045,809

Commitments and contingencies (Note 10)



Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss
(expressed in Canadian dollars)
(unaudited)

	Note	For the three months ended September 30		For the nine months ended September 30	
		2025	2024	2025	2024
Revenue		\$ 275,657	\$ 22,417	\$ 1,052,597	\$ 22,417
Cost of goods sold	5	206,972	7,835	657,696	7,835
Gross Profit		68,685	14,582	394,901	14,582
Expenses:					
Selling, general and administrative		244,995	72,153	579,478	370,112
Research and development		11,995	171,320	13,108	403,382
		256,990	243,473	592,586	773,494
Loss before the undernoted		(188,305)	(228,891)	(197,685)	(758,912)
Finance income:					
Finance expense, net		48,156	41,815	131,851	110,924
Foreign exchange loss (gain)		(106)	2,205	(29,261)	12,035
		48,050	44,020	102,590	122,959
Net loss before income taxes		(236,355)	(272,911)	(300,275)	(881,871)
Income tax expense		1,631	-	1,631	-
Net loss		\$ (237,986)	\$ (272,911)	\$ (301,906)	\$ (881,871)
Translation adjustment		14,855	1,196	(28,059)	1,242
Comprehensive loss		\$ (223,141)	\$ (271,715)	\$ (329,965)	\$ (880,629)
Loss per share attributable to shareholders:					
Basic and Diluted	9(e)	\$ 0.00	\$ (0.01)	\$ (0.01)	\$ (0.02)
Weighted average shares outstanding:					
Basic and Diluted	9(e)	54,000,000	54,000,000	54,000,000	54,000,000



Condensed Consolidated Interim Statements of Changes in Equity
 (expressed in Canadian dollars)
 (unaudited)

	Note	Share Capital	Warrants	Contributed surplus	Accumulated other comprehensive loss	Deficit	Total
Balance, December 31, 2023		\$ 7,000,100	\$ 521,894	\$ 809,420	\$ (73,005)	\$ (9,395,144)	\$ (1,136,735)
Net loss for the nine months ended September 30, 2024		-	-	-	-	(881,871)	(881,871)
Other comprehensive income for the nine months ended September 30, 2024		-	-	-	1,242	-	1,242
Balance, September 30, 2024		\$ 7,000,100	\$ 521,894	\$ 809,420	\$ (71,763)	\$ (10,277,015)	\$ (2,017,364)
Balance, December 31, 2024		\$ 7,000,100	\$ 521,894	\$ 809,420	\$ (20,755)	\$ (10,342,221)	\$ (2,031,562)
Net loss for the nine months ended September 30, 2025		-	-	-	-	(301,906)	(301,906)
Other comprehensive income for the nine months ended September 30, 2025		-	-	-	(28,059)	-	(28,059)
Balance, September 30, 2025		\$ 7,000,100	\$ 521,894	\$ 809,420	\$ (48,814)	\$ (10,644,127)	\$ (2,361,527)



Condensed Consolidated Interim Statements of Cash Flows
 (expressed in Canadian dollars)
 (unaudited)

For the nine months ended September 30	Note	2025	2024
Cash (used in) provided by:			
Operating activities:			
Net loss for the period		\$ (301,906)	\$ (881,871)
Finance expense, net		131,851	110,924
Income tax expense		1,631	-
Amortization of property and equipment		21,530	934
Amortization of intangible assets	7	40,993	2,302
Amortization of other asset	9(d)	78,284	78,284
Foreign exchange loss (gain)		(29,261)	12,035
Interest paid, net		(118,852)	(111,062)
Income tax paid		(3,000)	-
Changes in working capital accounts:			
Accounts receivable	4	152,902	80,029
Inventory	5	1,336	(168,741)
Prepaid expenses		15,470	185,388
Accounts payable and accrued liabilities		(359,660)	376,028
Cash used in from operating activities		(368,682)	(315,750)
Financing activities:			
Bank indebtedness	6	180,046	1,113,684
Repayment of lease liability		(25,058)	-
Cash flows from financing activities		154,988	1,113,684
Investing activities:			
Acquisition of C&R Pharmacy	3	(219,123)	(611,650)
Proceeds from sale of non-current assets	8	264,520	-
Cash flows from investing activities		45,397	(611,650)
Increase (decrease) in cash		\$ (168,297)	\$ 186,284
Cash, beginning of period		235,929	53,015
Cash, end of period		\$ 67,632	\$ 239,299



Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

1. Reporting entity:

Waverley Pharma Inc. ("**Waverley**" or the "**Company**") was incorporated as Buffalo Capital Inc. ("**Buffalo**") pursuant to the provisions of the Canada Business Corporations Act ("**CBCA**") on December 14, 2016 and was classified as a Capital Pool Corporation ("**CPC**") as defined by Policy 2.4 of the TSX Venture Exchange (the "**Exchange**"). On October 24, 2017, the Company completed a qualifying transaction (the "**QT**") with Waverley Pharma Inc. and resumed as Waverley Pharma Inc. in accordance with the CBCA.

The Company is domiciled and incorporated in Canada and its Common Shares are listed on Tier 2 of the Exchange under the symbol "WAVE". The address of the Company's registered office and head office is 4-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.

The Company is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. The Company has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited ("**RLS**" or the "**Licensor**") by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (the "**UK**") and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. Additionally, the Company has acquired exclusive territorial licenses from RLS to two oncologic drugs currently under development, pemetrexed and bortezomib in the United States and its territories (the "**USA**"), Canada, and the European Union (the "**EU**"). In addition, the Company has obtained a non-exclusive license to sell both pemetrexed and bortezomib in the UK. These products are marketed in the EU and the UK through the Company's wholly owned Irish subsidiary, Waverley Pharma Europe Limited ("**WPEL**"). During 2023, the Company elected to scale back its commercial operations in the UK and the EU due to increased competition and as a result, the Company has shifted its focus back to its research and development projects, including the development of its PARP-1 inhibitor.

On September 18, 2024, the Company, acquired 100% membership interest in C&R Pharmacy, LLC ("**C&R Pharmacy**"), a retail pharmacy located in West Liberty, Ohio. C&R Pharmacy accepts all major insurance providers and is strategically located in rural Ohio, where there is limited competition.

2. Basis of preparation:

(a) Statement of compliance

These condensed consolidated interim financial statements, including comparatives, have been prepared in accordance with International Financial Reporting Standards ("**IFRS**") as issued by the International Accounting Standards Board ("**IASB**") and Interpretations issued by the International Financial Reporting Interpretations Committee ("**IFRIC**").

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard ("**IAS**") 34 *Interim Financial Reporting* and have been prepared using the same accounting policies and methods of application as those used in the Company's audited consolidated financial statements for the year ended December 31, 2024. These condensed consolidated interim financial statements do not include all of the information required for full annual consolidated financial statements and should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2024.

These condensed consolidated interim financial statements were authorized for issue by the Board of Directors (the "**Board**") on November 26, 2025.

(b) Basis of presentation

These condensed consolidated interim financial statements have been prepared on the historical cost basis except for financial instruments at fair value through profit or loss ("**FVTPL**") which are measured at fair value.

(c) Going concern

These condensed consolidated interim financial statements have been prepared on a going concern basis which contemplates the realization of assets and the payment of liabilities in the ordinary course of business. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets and meet its liabilities as they become due.

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

2. Basis of preparation (continued):

(c) Going concern (continued)

The Company is a research and development stage company and as such is primarily dependent on financing provided from external sources to continue as a going concern. Management intends to use its available funding to improve its current operations, and increase revenue in order to fund future operations, however, the outcome of these matters cannot be predicted at this time. In addition, during the nine month period ended September 30, 2025, the company incurred a net loss of \$301,906 (2024 – \$881,871), with cash used in operating activities of \$368,682 (2024 - \$315,750) and, as at September 30, 2025 has a deficit of \$10,644,127 (December 31, 2024 - \$10,342,221).

(d) Functional and presentation currency

The condensed consolidated interim financial statements are presented in Canadian dollars, which is the Company's functional currency. All financial information presented has been rounded to the nearest dollar except where indicated otherwise.

(e) Use of estimates and judgments

The preparation of the condensed consolidated financial statements in conformity with IFRS requires management to make estimates, judgements and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenue and expenses during the period.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Areas in which management has made critical judgments in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements include the determination of the Company's and its subsidiaries' functional currencies.

Information about key assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year are included in the following notes to the consolidated financial statements for the year ended December 31, 2024:

- Note 3(i): Estimates of the valuation of intangible assets
- Note 3(q): The measurement and valuation of intangible assets and contingent consideration acquired and recorded as business combinations

3. Business combinations and goodwill

On September 18, 2024, the Company acquired 100% membership interest of C&R Pharmacy, a retail pharmacy located in West Liberty, Ohio, for cash consideration of \$830,673. The purchase agreement included contingent consideration of an additional payment (the "First Anniversary Payment") to the seller based on the achievement of certain future performance targets by C&R Pharmacy. The contingent payment is based on a one-year revenue target of USD\$ 1.4 million (based on C&R Pharmacy's historical revenue) for the period September 18, 2024 to September 17, 2025. If the revenue target is met, the seller would be obligated to receive an additional USD\$60,000. Based on management's assessment, it was determined that the First Anniversary Payment performance target would not be met. As a result, the Company has not recorded any contingent consideration liabilities on its condensed consolidated statement of financial position. In addition, the Company was required to purchase up to a maximum of USD\$180,000 of prescription inventory, based on the seller's inventory on hand at the time of acquisition. At the time of acquisition, it was determined that the seller had USD\$161,238 of inventory which was paid to the seller during the nine month period ended September 30, 2025.

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

3. Business combinations and goodwill (continued)

The following table summarizes the finalized fair values of the identifiable assets and liabilities as at the date of the acquisition:

Net assets acquired	
Inventory	\$ 219,123
Property and equipment	9,513
Right of use asset	247,160
Pharmacy license	133,234
Customer lists	193,615
Brand name	64,042
Goodwill	211,146
Current portion of lease obligation	(30,221)
Lease obligation	(216,939)
Net assets acquired	\$ 830,673
Summary of purchase consideration	
Cash paid	\$ 830,673
Amount outstanding at period-end	-
Purchase consideration	\$ 830,673

During the nine month period ended September 30, 2025, \$219,123 of the remaining purchase consideration was paid to the seller in relation to inventory acquired as part of the acquisition.

The changes in the value of goodwill are summarized in the table below:

At December 31, 2023	\$ -
Acquisition of C&R Pharmacy	211,146
Effects of movements in exchange rates	12,414
At December 31, 2024	\$ 223,560
Effects of movements in exchange rates	(7,271)
At September 30, 2025	\$ 216,289

4. Accounts receivable

	September 30, 2025	December 31, 2024
Trade accounts receivable	\$ 51,336	\$ 53,062
Other accounts receivable	4,443	155,619
	\$ 55,779	\$ 208,681

As at September 30, 2025 and December 31, 2024 there were no customer(s) with amounts owing greater than 10% of the Company's trade accounts receivable.

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

5. Inventory

Inventory consists of finished product available for sale to customers. During the three and nine month periods ended September 30, 2025, inventory expensed as part of cost of goods sold totaled \$206,972 and \$657,696 respectively, (2024 – \$7,835 and \$7,835). Cost of goods sold recorded during the current periods related to products sold through C&R Pharmacy.

6. Bank indebtedness

The Company currently has access to a line of credit from its primary financial institution for maximum aggregate proceeds of \$3,500,000. The line of credit carries a floating interest rate on standard commercial terms, calculated daily, and is repayable as to principal amount drawn and accrued and unpaid interest thereon upon demand. As at September 30, 2025, the drawn amount on the line of credit is \$2,990,429 (December 31, 2024 – \$2,810,383). During the three and nine month period ended September 30, 2025, the amount of interest paid in relation to the line of credit was \$40,278 and \$118,852, respectively (2024 – \$41,233 and \$111,062), and is included within finance expense on the condensed consolidated interim statement of net loss and comprehensive loss. The collateral for the line of credit was provided by a director of the Company (see note 9(d) and note 11(b) below for more information).

7. Intangible assets

Cost	Licenses	Customer list	Brand names and trademarks	Total
At December 31, 2023	\$ -	\$ -	\$ -	\$ -
Additions	133,234	193,615	64,042	390,891
Effect of movements in exchange rates	7,833	11,383	3,765	22,981
At December 31, 2024	\$ 141,067	\$ 204,998	\$ 67,807	\$ 413,872
Effect of movements in exchange rates	(4,588)	(6,667)	(2,205)	(13,460)
At September 30, 2025	\$ 136,479	\$ 198,331	\$ 65,602	\$ 400,412

Accumulated amortization	Licenses	Customer list	Brand names and trademarks	Total
At December 31, 2023	\$ -	\$ -	\$ -	\$ -
Amortization	5,525	8,042	1,860	15,427
Effect of movements in exchange rates	184	256	61	501
At December 31, 2024	\$ 5,709	\$ 8,298	\$ 1,921	\$ 15,928
Amortization	14,695	21,354	4,944	40,993
Effect of movements in exchange rates	(257)	(374)	(86)	(717)
At September 30, 2025	\$ 20,147	\$ 29,278	\$ 6,779	\$ 56,204

Carrying amounts	Licenses	Customer list	Brand names and trademarks	Total
At December 31, 2024	\$ 135,358	\$ 196,700	\$ 65,886	\$ 397,944
At September 30, 2025	\$ 116,332	\$ 169,053	\$ 58,823	\$ 344,208



Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

7. Intangible assets (continued)

Intangible assets acquired during the year ended December 31, 2024 were all in relation to the Company's acquisition of C&R Pharmacy. For more information regarding the acquisition of C&R Pharmacy, see note 3 – business combinations and goodwill. The assets acquired as part of the C&R Pharmacy acquisition have the following remaining useful life as at September 30, 2025:

Intangible asset	Remaining useful life
Pharmacy license	6.00 years
Customer list	6.00 years
Brand names and trademarks	9.00 years

For the three and nine month periods ended September 30, 2025, amortization of intangible assets totaling \$13,455 and \$40,993, respectively, (2024 – nil and nil) is recorded within selling, general and administrative expenses on the condensed consolidated statement of net loss and comprehensive loss.

The Company has considered indicators of impairment as at September 30, 2025 and 2024 and did not record an impairment charge in either the three month or nine month periods ended September 30, 2025 or 2024.

8. Non-current assets held-for-sale

Cost	Licenses
Balance, December 31, 2023	\$ 264,520
Balance, December 31, 2024	264,520
Derecognition	(264,520)
Balance, September 30, 2025	\$ -

On August 30, 2017, the Company acquired exclusive territorial licenses from RLS to sell and market two generic cancer drugs, pemetrexed and bortezomib in the USA, Canada and the EU (excluding the UK where a non-exclusive territorial license was acquired).

During the year ended December 31, 2024, the Company entered into an amendment to the August 30, 2017 agreement with RLS whereby Waverley Pharma agreed to transfer the ownership of the US Abbreviated New Drug Applications for both pemetrexed and bortezomib, back to RLS. During the nine month period ended September 30, 2025, the transfer of the non-current assets held-for-sale was completed, in exchange for total consideration of \$264,520.

9. Capital stock

(a) Authorized

The Company has authorized share capital of an unlimited number of common voting shares.

(b) Shares issued and outstanding

Shares issued and outstanding are as follows:

	Number of Common Shares	Amount
Balance, December 31, 2023	54,000,000	\$ 7,000,100
Balance, December 31, 2024	54,000,000	\$ 7,000,100
Balance, September 30, 2025	54,000,000	\$ 7,000,100

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

9. Capital stock (continued)

(c) Stock option plan

The Company has an incentive stock option plan (the “Plan”) whereby the Company may grant directors, officers, employees and contractors incentive stock options to purchase voting common shares of the Company. The terms and conditions of each option granted under the Plan are determined by the Board. The number of common shares reserved for issuance upon the exercise of options is limited to a maximum of 10% of the issued and outstanding common shares of the Company at any time.

Changes in the number of options outstanding during the nine months ended September 30, 2025 and 2024 are as follows:

For the nine months ended September 30	2025		2024	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Balance, beginning of period	750,000	\$ 0.29	1,075,000	\$ 0.34
Forfeited/expired	(225,000)	\$ (0.10)	(325,000)	\$ (0.47)
Balance, end of period	525,000	\$ 0.37	750,000	\$ 0.29
Options exercisable, end of period	525,000	\$ 0.37	750,000	\$ 0.29

The following is a summary of the 525,000 outstanding options issued under the Plan:

Exercise price	Number outstanding	Weighted average remaining contractual life	Number exercisable	Weighted average remaining vesting period
\$0.200	225,000	1.5 years	225,000	-
\$0.500	300,000	2.0 years	300,000	-
	525,000		525,000	

(d) Warrants

Changes in the number of warrants outstanding during the period ended September 30, 2025 and 2024 are as follows:

Period ended September 30	2025		2024	
Warrants	Weighted average exercise price	Warrants	Weighted average exercise price	
Balance, beginning of period	10,000,000	\$ 0.11	10,000,000	\$ 0.11
Balance, end of period	10,000,000	\$ 0.11	10,000,000	\$ 0.11

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

9. Capital stock (continued)

(d) Warrants (continued)

On August 05, 2021, the Company entered into an agreement with its primary financial institution, pursuant to which the financial institution provided the Company with a line of credit with maximum aggregate proceeds of \$3,000,000. The collateral necessary to secure the line of credit was provided by a director of the Company. To compensate the director for providing the collateral for the line of credit, the Company granted the director 10,000,000 warrants. Each warrant entitles the holder to purchase one (1) common share of the Company and are exercisable within five years of the date of grant at an exercise price of \$0.11 per common share. On the initial grant date of the warrants the Company recognized an other asset on its consolidated statement of financial position of \$521,894 as a result of this arrangement, equal to the fair value of the warrants issued, which were calculated using the Black-Scholes pricing model.

For the three and nine month periods ended September 30, 2025, amortization of \$26,095 and \$78,284 (2024 - \$26,095 and \$78,284), respectively was recorded within selling, general, and administrative expenses on the condensed consolidated statement of net loss and comprehensive loss as a result of this transaction.

(e) Per share amounts

The weighted average number of common voting shares outstanding for the period ended September 30, 2025 and 2024 was 54,000,000. Effects of dilution from 525,000 (2024 – 750,000) options and 10,000,000 (2024 – 10,000,000) warrants were excluded from the calculation of weighted average shares outstanding for diluted loss per share for the three and nine month period ended September 30, 2025 and 2024 as they are anti-dilutive.

10. Commitments and contingencies

(a) Commitments

As at September 30, 2025, and in the normal course of business, the Company has obligations to make future payments representing contracts and other commitments that are known and committed. The Company, through a subsidiary, C&R Pharmacy, has committed to a retail space lease at a monthly rate of USD\$2,000. The Company's lease obligation has a term ending in 2029.

(b) Contingencies

In the normal course of business, the Company may from time to time be subject to various claims or possible claims. Although management currently believes there are no claims or possible claims that if resolved would either individually or collectively result in a material adverse impact on the Company's financial position, results of operations, or cash flows, these matters are inherently uncertain and management's view of these matters may change in the future.

Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

11. Related party transactions

(a) Key management personnel compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. The Board of Directors, CEO and CFO of the Company are considered to be key management personnel. The Chief Executive Officer of the Company is a consultant through a consulting agreement which was signed on February 1, 2020.

The following table details the compensation paid to key management personnel:

	Three months ended September 30		Nine months ended September 30	
	2025	2024	2025	2024
Salaries and fees	\$ 10,500	\$ 12,000	\$ 33,500	\$ 49,500
	\$ 10,500	\$ 12,000	\$ 33,500	\$ 49,500

Directors and key management personnel control 75% of the voting shares of the Company as at September 30, 2025 (December 31, 2024 - 75%).

(b) Transactions with related parties

During the three and nine months ended September 30, 2025, the Company paid GVI Clinical Development Solutions Inc. ("GVI CDS"), a company controlled by a director of the Company, a total of nil and \$47,806, respectively (2024 – \$10,689 and \$52,520) for regulatory affairs consulting.

During the three and nine months ended September 30, 2024, the Company paid CanAm Bioresearch Inc. ("CanAm"), a company controlled by a director of the Company, \$33,000 and \$132,000, respectively, for research services in connection with the Company's PARP-1 development project. During the three and nine month period ended September 30, 2025, the Company did not pay any amounts to CanAm.

These transactions were in the normal course of business and have been measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. As at September 30, 2025, included in accounts payable and accrued liabilities is \$2,109 (December 31, 2024 - \$47,714) payable to GVI CDS.

Effective May 1, 2024, the Company amended its agreement with its CEO, amending the annual fee from \$45,000 to \$24,000. Effective May 1, 2025, the Company amended its agreement with its CEO, amending the annual fee from \$24,000 to \$18,000. The Company can terminate the agreement with 30 days written notice, otherwise the agreement has an indefinite term. As at September 30, 2025, included within accounts payable and accrued liabilities is \$1,500 payable to the CEO as a result of this agreement (December 31, 2024 – \$4,000).

Effective May 1, 2024, the Company amended its agreement with its CFO through 10055098 Manitoba Ltd., amending the annual fee from \$43,500 to \$24,000. The fee is reviewed annually on or about January 1. The Company can terminate the agreement with 30 days written notice, otherwise the agreement has an indefinite term. As at September 30, 2025 there were no amounts payable to 10055098 Manitoba Ltd as a result of this agreement (December 31, 2024 – nil).

On August 05, 2021, the Company entered into an agreement with its primary financial institution, pursuant to which the financial institution provided the Company with a line of credit with maximum aggregate proceeds of \$3,000,000. The collateral necessary to secure the line of credit was provided by a director of the Company. To compensate the director for providing the collateral for the line of credit, the Company granted the director 10,000,000 warrants. Each warrant entitles the holder to purchase one (1) common share of the Company and is exercisable within five years of the date of grant at an exercise price of \$0.11 per common share.



Notes to the Condensed Consolidated Interim Financial Statements
(expressed in Canadian dollars)
(unaudited)

12. Segmented information

The Company operates in one business segment, the biopharmaceutical industry.

Revenue generated from external customers for the three and nine month periods ended September 30, 2025 was 100% from sales to retail pharmacy customers in the United States.

The Company's property and equipment, intangible assets and goodwill are all located within the United States.